Breiman Richard S, Coakley Fergus V, Webb Emily M, Ellingson James J, Roberts John P, Kohr Jennifer, Lutz Juergen, Knoess Naomi, Yeh Benjamin M
Departments of Radiology and Surgery, University of California San Francisco, 505 Parnassus Ave, Box 0628, San Francisco, CA 94143-0628, USA.
Radiology. 2008 Jun;247(3):733-7. doi: 10.1148/radiol.2473070964. Epub 2008 Apr 18.
To retrospectively determine whether premedication with intravenously administered morphine improves bile duct caliber and visualization in potential liver donors undergoing computed tomographic (CT) cholangiography.
This was a retrospective single institution study approved by the institutional review board and compliant with requirements of the HIPAA. Multidetector CT cholangiography was performed after slow infusion of 20 mL of iodipamide meglumine 52% diluted in 80 mL of normal saline in 143 consecutive potential liver donors (81 men and 62 women; mean age, 37 years); 43 received premedication with intravenous morphine sulfate (0.04 mg per kilogram of body weight) and 100 did not. Two independent readers recorded common bile duct diameter and area on axial CT images. Readers also scored bile duct visualization, including all second-order biliary branches, on a four-point scale (0, not seen; 3, excellent visualization).
For scans obtained without and those obtained with morphine, there was no significant difference in the mean common bile duct diameter (4.1 vs 4.3 mm for reader 1 and 4.4 vs 4.6 mm for reader 2, respectively; P > .39 for both readers), in common bile duct area (20.7 vs 21.5 mm(2), for reader 1 and 21.3 vs 20.2 mm(2) for reader 2, respectively, P > .60 for both), or in second-order bile duct visualization score (2.34 vs 2.36 for reader 1 and 2.58 vs 2.50 for reader 2, respectively; P > .5 for both).
The results suggest that premedication with intravenous morphine prior to CT cholangiography in potential liver donors does not increase bile duct caliber or improve biliary visualization.
回顾性确定静脉注射吗啡进行预处理是否能改善接受计算机断层扫描(CT)胆管造影的潜在肝脏供体的胆管管径及显影情况。
这是一项经机构审查委员会批准且符合健康保险流通与责任法案(HIPAA)要求的回顾性单机构研究。对143例连续的潜在肝脏供体(81例男性和62例女性;平均年龄37岁)缓慢输注20 mL 52%的碘番酸葡甲胺并稀释于80 mL生理盐水中后进行多排CT胆管造影;43例接受静脉注射硫酸吗啡(0.04 mg/千克体重)预处理,100例未接受。两名独立阅片者在轴向CT图像上记录胆总管直径和面积。阅片者还对胆管显影情况进行评分,包括所有二级胆管分支,采用四点量表(0分,未见;3分,显影极佳)。
对于未用吗啡及使用吗啡的扫描,两名阅片者的胆总管平均直径(阅片者1分别为4.1 vs 4.3 mm,阅片者2分别为4.4 vs 4.6 mm;两名阅片者P均>.39)、胆总管面积(阅片者1分别为20.7 vs 21.5 mm²,阅片者2分别为21.3 vs 20.2 mm²,两名阅片者P均>.60)或二级胆管显影评分(阅片者1分别为2.34 vs 2.36,阅片者分别为2.58 vs 2.50;两名阅片者P均>.5)均无显著差异。
结果表明,潜在肝脏供体在CT胆管造影前静脉注射吗啡预处理不会增加胆管管径或改善胆管显影。